What is more, the predictive significance of IgM+ memory B cells was validated in another cohort of advanced NSCLC patients receiving anti-PD-1 monotherapy (cohort 2 in Table 1, n = 70). This evidence concerns the gene CD40LG and non-small cell lung carcinoma.